DMedical announced today that it received CE mark approval for its CT:VQ SaaS imaging platform and raised approximately $60 million.

CT:VQ™ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance to 4DMedical’s non-contrast, computed tomography (CT)-based ventilation-perfusion imaging technology, CT:VQ, for respiratory ...

4DMedical Limited has unveiled its innovative CT:VQ technology at RSNA 2024, offering a revolutionary alternative to traditional Nuclear VQ scans. This new imaging solution promises faster, safer, and ...

Hi, everyone. Thank you so much for joining us today and for your interest in 4DMedical and today's investor presentation. Of course, the key focus of today's presentation is going to be CT:VQ post ...

Hey everybody. Really, thank you so much for joining this call. I'm incredibly appreciative of your interest. I hope you can bear with me. My voice is pretty hoarse. I've literally had hundreds and ...

Australian respiratory imaging technology company 4dmedical Ltd. raised AU$150 million (US$105 million) in an institutional placement to accelerate U.S. adoption of its CT:VQ lung imaging software to ...